Scarica l'app Stockscreener
319.43
0.31%
-0.99
Dopo l'orario di chiusura:
320.00
0.57
+0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Form 4 Ligand Pharmaceuticals Incorporated For: 6 July By Investing.com - Investing.com Canada
Ligand Pharmaceuticals CLO Andrew Reardon sells $1.56m in shares By Investing.com - Investing.com Canada
[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Ligand Pharmaceuticals (LGND) CFO adds 17 shares through stock purchase plan - Stock Titan
LGND CEO Todd Davis acquires stock through employee plan in Form 4 filing - Stock Titan
Ligand Pharmaceuticals stock hits all-time high at 321.33 USD - Investing.com
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Ligand Pharmaceuticals explores licensing-driven growth as investors assess its royalty model - AD HOC NEWS
Ligand Pharmaceuticals Is Buying Xoma for Nearly $740 Million -- WSJ - Moomoo
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals Incorporated Bonds — Corporate Bond Rates - TradingView
US53220KAJ7 Bond Analysis — Key Metrics - TradingView
US53220KAJ7 Bond Price and Chart — FWB:US53220KAJ7 - TradingView
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
LGND: 10,000-share Section 144 notice; prior 10b5-1 sales by Reardon (LGND) - Stock Titan
Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharma: Expect Bright And Exciting Future For This Growing Royalty Aggregator - Seeking Alpha
Price to sales forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals reaches new 52-week high as insiders trim holdings - AD HOC NEWS
Zerion Pharma completes royalty financing and equity investment transaction with Ligand to advance the Dispersome® technology - marketscreener.com
Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView
Price to sales forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNDZ - TradingView
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 2000 Value Benchmark - marketscreener.com
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView
Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView
Price to earnings forward of Ligand Pharmaceuticals Incorporated – NASDAQ:LGND - TradingView
Price to earnings forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView
Price to book forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell 3000 Value Benchmark - marketscreener.com
Price to sales forward of Ligand Pharmaceuticals Incorporated – BX:LGDN - TradingView
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition - Yahoo Finance
Ligand Pharmaceuticals Incorporated Actuals & Estimates (NASDAQ:LGND) - TradingView
Ligand completes $700m convertible notes offering By Investing.com - Investing.com Australia
LGND Forecast — Price Target — Prediction for 2027 - TradingView
Ligand Pharmaceuticals Inc (LGND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ligand Pharmaceuticals Incorporated Actuals & Estimates (SWB:LGDN) - TradingView
Ligand completes $700m convertible notes offering - Investing.com UK
LGDN Forecast — Price Target — Prediction for 2027 - TradingView
Ligand Pharmaceuticals Incorporated Actuals & Estimates (BOATS:LGND) - TradingView
Ligand Pharmaceuticals Prices Upsized $625 Million Zero-Coupon Convertible Notes Offering to Boost Financial Flexibility and Offset Dilution 1 – Minichart - Minichart
Ligand Raises $700M Via 0% Convertible Notes, Adds Note Hedges and $524.34 Strike Warrants - TradingView
Ligand (Nasdaq: LGND) raises $700M in 0% convertible notes with hedges - Stock Titan
Ligand Pharmaceuticals stock hits all-time high at 289.0 USD By Investing.com - Investing.com Australia
Ligand Announces Closing of Convertible Senior Notes Offering - The Manila Times
Press Release: Ligand Announces Closing of Convertible Senior Notes Offering - Moomoo
Ligand Pharmaceuticals stock hits all-time high at 289.0 USD - Investing.com
Ligand Pharmaceuticals Hits New 52-Week High of $282.53 - MarketsMojo
Ligand Pharmaceuticals Inc (LGND) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ligand (LGND) Announces Convertible Senior Notes Offering - GuruFocus
LGND Stock Rips Higher As Royalty Story Deepens - StocksToTrade
LGND Stock Draws Traders As Royalties Rise, Debt Deal Hits - StocksToTrade
Ligand prices $625 million convertible notes offering By Investing.com - Investing.com Australia
Ligand Pharmaceuticals (LGND) Prices $625M Convertible Senior No - GuruFocus
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):